nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A7—Cyclosporine—focal segmental glomerulosclerosis	0.269	0.329	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Cyclosporine—focal segmental glomerulosclerosis	0.269	0.329	CbGbCtD
Ethosuximide—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.202	0.247	CbGbCtD
Ethosuximide—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0787	0.0961	CbGbCtD
Ethosuximide—Gingival hypertrophy—Cyclosporine—focal segmental glomerulosclerosis	0.0509	0.29	CcSEcCtD
Ethosuximide—Swollen tongue—Cyclosporine—focal segmental glomerulosclerosis	0.0144	0.0823	CcSEcCtD
Ethosuximide—Hirsutism—Cyclosporine—focal segmental glomerulosclerosis	0.00729	0.0416	CcSEcCtD
Ethosuximide—Gastrointestinal symptom NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00721	0.0411	CcSEcCtD
Ethosuximide—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00721	0.0411	CcSEcCtD
Ethosuximide—Libido increased—Cyclosporine—focal segmental glomerulosclerosis	0.00697	0.0398	CcSEcCtD
Ethosuximide—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00583	0.0333	CcSEcCtD
Ethosuximide—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00489	0.0279	CcSEcCtD
Ethosuximide—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.00424	0.0242	CcSEcCtD
Ethosuximide—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00368	0.021	CcSEcCtD
Ethosuximide—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00314	0.0179	CcSEcCtD
Ethosuximide—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00305	0.0174	CcSEcCtD
Ethosuximide—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00281	0.016	CcSEcCtD
Ethosuximide—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.0159	CcSEcCtD
Ethosuximide—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00277	0.0158	CcSEcCtD
Ethosuximide—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00255	0.0145	CcSEcCtD
Ethosuximide—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00241	0.0137	CcSEcCtD
Ethosuximide—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.0129	CcSEcCtD
Ethosuximide—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0021	0.012	CcSEcCtD
Ethosuximide—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00209	0.0119	CcSEcCtD
Ethosuximide—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00209	0.0119	CcSEcCtD
Ethosuximide—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.0109	CcSEcCtD
Ethosuximide—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00186	0.0106	CcSEcCtD
Ethosuximide—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00185	0.0106	CcSEcCtD
Ethosuximide—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.0102	CcSEcCtD
Ethosuximide—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.00972	CcSEcCtD
Ethosuximide—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00166	0.00946	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00157	0.00894	CcSEcCtD
Ethosuximide—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00148	0.00846	CcSEcCtD
Ethosuximide—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00838	CcSEcCtD
Ethosuximide—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00823	CcSEcCtD
Ethosuximide—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00767	CcSEcCtD
Ethosuximide—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.0075	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00745	CcSEcCtD
Ethosuximide—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00744	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.00706	CcSEcCtD
Ethosuximide—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00686	CcSEcCtD
Ethosuximide—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00682	CcSEcCtD
Ethosuximide—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00636	CcSEcCtD
Ethosuximide—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00619	CcSEcCtD
Ethosuximide—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.0059	CcSEcCtD
Ethosuximide—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.001	0.00571	CcSEcCtD
Ethosuximide—CACNA1G—NCAM1 interactions—COL4A4—focal segmental glomerulosclerosis	0.000971	0.153	CbGpPWpGaD
Ethosuximide—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000961	0.00549	CcSEcCtD
Ethosuximide—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000953	0.00544	CcSEcCtD
Ethosuximide—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000952	0.00544	CcSEcCtD
Ethosuximide—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000947	0.00541	CcSEcCtD
Ethosuximide—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000898	0.00513	CcSEcCtD
Ethosuximide—CACNA1G—NCAM1 interactions—COL4A1—focal segmental glomerulosclerosis	0.000892	0.141	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM1 interactions—COL4A3—focal segmental glomerulosclerosis	0.000754	0.119	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—COL4A4—focal segmental glomerulosclerosis	0.000571	0.09	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—COL4A1—focal segmental glomerulosclerosis	0.000524	0.0827	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—COL4A3—focal segmental glomerulosclerosis	0.000443	0.0699	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MYH10—focal segmental glomerulosclerosis	0.000221	0.0349	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—COL4A4—focal segmental glomerulosclerosis	0.000164	0.0258	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MYH10—focal segmental glomerulosclerosis	0.000158	0.0249	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—COL4A1—focal segmental glomerulosclerosis	0.00015	0.0237	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—COL4A3—focal segmental glomerulosclerosis	0.000127	0.02	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MYH9—focal segmental glomerulosclerosis	0.000121	0.0191	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—focal segmental glomerulosclerosis	0.000121	0.019	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.000117	0.0184	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.000107	0.0169	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—TRPC6—focal segmental glomerulosclerosis	9.35e-05	0.0147	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	9.07e-05	0.0143	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—focal segmental glomerulosclerosis	9.07e-05	0.0143	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MYH9—focal segmental glomerulosclerosis	8.65e-05	0.0136	CbGpPWpGaD
Ethosuximide—CYP2E1—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	7.69e-05	0.0121	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	6.67e-05	0.0105	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—LPL—focal segmental glomerulosclerosis	4.19e-05	0.00661	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MMP2—focal segmental glomerulosclerosis	3.94e-05	0.00621	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MMP9—focal segmental glomerulosclerosis	2.96e-05	0.00467	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MMP2—focal segmental glomerulosclerosis	2.81e-05	0.00443	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—LIPC—focal segmental glomerulosclerosis	2.44e-05	0.00384	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CTGF—focal segmental glomerulosclerosis	2.15e-05	0.00338	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.11e-05	0.00333	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.98e-05	0.00312	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.74e-05	0.00275	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—LPL—focal segmental glomerulosclerosis	1.49e-05	0.00234	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—AGT—focal segmental glomerulosclerosis	1.27e-05	0.00201	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—LIPC—focal segmental glomerulosclerosis	9.81e-06	0.00155	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ALB—focal segmental glomerulosclerosis	9.76e-06	0.00154	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CTGF—focal segmental glomerulosclerosis	8.64e-06	0.00136	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.96e-06	0.00126	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—LIPC—focal segmental glomerulosclerosis	7.11e-06	0.00112	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	7.09e-06	0.00112	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CTGF—focal segmental glomerulosclerosis	6.26e-06	0.000987	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	6.25e-06	0.000985	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—LPL—focal segmental glomerulosclerosis	5.99e-06	0.000944	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.77e-06	0.000909	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.75e-06	0.000907	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—AGT—focal segmental glomerulosclerosis	5.12e-06	0.000808	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—LPL—focal segmental glomerulosclerosis	4.34e-06	0.000684	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	4.33e-06	0.000683	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ALB—focal segmental glomerulosclerosis	3.93e-06	0.00062	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—AGT—focal segmental glomerulosclerosis	3.71e-06	0.000585	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	3.7e-06	0.000584	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	3.3e-06	0.00052	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	2.9e-06	0.000458	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ALB—focal segmental glomerulosclerosis	2.85e-06	0.000449	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	2.84e-06	0.000448	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.68e-06	0.000422	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	2.01e-06	0.000317	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	1.72e-06	0.000271	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	1.32e-06	0.000208	CbGpPWpGaD
